Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NMT2 | O60551 | 2/20 | 0.39 |
| ▸ | NMT1 | P30419 | 2/20 | 0.39 |
| ▸ | CTSL | P07711 | 1/20 | 0.38 |
| ▸ | FAP | Q12884 | 3/20 | 0.37 |
| ▸ | FURIN | P09958 | 6/20 | 0.37 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.36 |
| ▸ | TLR2 | O60603 | 1/20 | 0.36 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.35 |
| ▸ | PRKACA | P17612 | 1/20 | 0.35 |
| ▸ | AKT3 | Q9Y243 | 1/20 | 0.35 |
| ▸ | HRH1 | P35367 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20349812 | 1.00 | NMT2 (0.39) | NMT2NMT1CTSLFAPFURIN | |
| SCHEMBL17860183 | 0.90 | NMT2 (0.40) | NMT2NMT1CTSLFAPFURIN | |
| SCHEMBL20287697 | 0.90 | NMT1 (0.38) | NMT2NMT1TLR2ROCK2PRKACA | |
| SCHEMBL22349913 | 0.89 | HRH1 (0.38) | NMT2NMT1CTSLFURINHRH1 | |
| SCHEMBL20349757 | 0.89 | HRH1 (0.38) | NMT2NMT1CTSLFURINHRH1 | |
| SCHEMBL17860132 | 0.87 | NMT1 (0.41) | NMT2NMT1CTSLFAPFURIN | |
| SCHEMBL20287670 | 0.87 | NMT1 (0.41) | NMT2NMT1CTSLFAPFURIN | |
| SCHEMBL22134346 | 0.87 | NMT1 (0.41) | NMT2NMT1CTSLFAPFURIN | |
| SCHEMBL24993722 | 0.86 | FURIN (0.42) | NMT2NMT1CTSLFURINPRSS1 | |
| SCHEMBL29647873 | 0.85 | FAP (0.38) | NMT2NMT1FAPFURINPRSS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180015176-A1 | ANTIBODY-DRUG CONJUGATES (ADCS) OF KSP INHIBITORS WITH AGLYCOSYLATED ANTI-TWEAKR ANTIBODIES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180015176-A1 | ANTIBODY-DRUG CONJUGATES (ADCS) OF KSP INHIBITORS WITH AGLYCOSYLATED ANTI-TWEAKR ANTIBODIES | TNFSF11, TNFRSF9, CD40 | NMT2 1316/4885NMT1 1230/4885CTSL 1456/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.